-
Zelgen Biopharmaceuticals’ Jacktinib Studies Selected for EHA Annual Meeting
•
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that the results of three clinical studies for its Category 1 drug jacktinib in myelofibrosis have been shortlisted for the European Hematology Association (EHA) annual meeting this year. Phase III Study: Jacktinib vs. Hydroxyurea in MyelofibrosisA randomized, double-blind Phase III study…
-
Zelgen Biopharmaceuticals’ ZG0895 Receives FDA Approval for Clinical Trials in Advanced Solid Tumors
•
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that it has received clinical trial approval from the US Food and Drug Administration (FDA) for its drug candidate ZG0895, which targets advanced solid tumors. ZG0895 is a highly selective toll-like receptor (TLR8) agonist developed in-house, designed to offer a new…
-
Coherent Biopharma Secures $100 Million in Series B and B+ Financings for Clinical Pipeline
•
Coherent Biopharma Ltd, a specialist in bispecific-ligand drug conjugates (Bi-XDC) headquartered in Suzhou, has declared the successful completion of Series B and Series B+ financing rounds, totaling $100 million. The initial Series B round was led by HM with support from Yuanfeng Capital, V Capital, 6 Dimensions Capital, Agricultural Bank…
-
Philips Agrees to $62 Million Settlement with SEC Over China Marketing Practices
•
The US Securities and Exchange Commission (SEC) has announced that Dutch device company Philips (BVMF: PHGN34) has agreed to a $62 million resolution to settle charges related to improper employee practices during the marketing of products in China between 2014 and 2019. In the settlement, which Philips accepted without admitting…
-
Peijia Medical Achieves Milestone with First Commercial Implants of Trilogy TAVR System in Hong Kong
•
Peijia Medical Limited (HKG: 9996), a leading China-based medical device company, has announced the successful completion of the first two commercial implants using its transcatheter aortic valve replacement (TAVR) product, the Trilogy heart valve system, in Hong Kong. This marks a significant milestone as the Trilogy system is the first…
-
BiOneCure Therapeutics and Nanjing Leads Biolabs Collaborate on Innovative ADCs for Solid Tumors
•
US-based biotech company BiOneCure Therapeutics Inc. has entered into a strategic collaboration with China-based Nanjing Leads Biolabs. The partnership aims to develop a range of innovative antibody drug conjugates (ADCs) that target solid tumors, marking a significant step in the advancement of cancer treatments. Combining Expertise to Target Solid TumorsBiOneCure…
-
Lynk Pharmaceuticals’ LNK01001 Demonstrates Efficacy in Phase II Rheumatoid Arthritis Study
•
China-based Lynk Pharmaceuticals Co., Ltd announced positive results from the Phase II clinical study of its drug candidate LNK01001 in treating rheumatoid arthritis (RA). The study demonstrated a statistically significant efficacy difference in terms of primary and key secondary endpoints, along with a favorable safety and tolerability profile. LNK01001: A…
-
Skyline Therapeutics Initiates Clinical Study with First Patient Dosing of SKG0106 for wAMD
•
Skyline Therapeutics has reached a significant milestone with the completion of the first patient dosing in its clinical study for SKG0106 intraocular injection solution. This in-house developed ophthalmology gene therapy was approved for clinical trials in China in December 2022. The open, dosage escalation study is designed to evaluate the…
-
Gracell Biotechnologies Initiates Trial for GC012F in Refractory SLE with Dual-Target FasTCAR Therapy
•
Gracell Biotechnologies Inc., (Nasdaq: GRCL), a China-based biopharmaceutical company, has announced the start of an investigator-initiated trial (IIT) in China for its therapeutic candidate GC012F. This candidate is an autologous FasTCAR therapy aimed at treating refractory systemic lupus erythematosus (SLE). The therapy is distinctive as a dual B cell maturation…
-
Aligos Therapeutics Partners with Amoytop Biotech for Oligonucleotide Compound R&D
•
Liver and viral disease specialist Aligos Therapeutics (NASDAQ: ALGS) announced last week a significant partnership with biopharmaceutical company Xiamen Amoytop Biotech (SHA: 688278) for the research and development (R&D) of live disease-targeting oligonucleotide compounds. These compounds are discovered using Aligos’s proprietary platform, marking a step forward in the treatment of…
-
CIM’s Cancer Vaccine CIMAvax Confirmed Immunogenic in US Study, Cuba Announces
•
The Cuba-based Molecular Immunology Center (CIM), part of the state-run conglomerate BioCubaFarma, has shared updates on the status of clinical trials (CTs) for two of its drug candidates being conducted abroad. CIM Director Tania Crombet revealed that a US study, in collaboration with the Roswell Park Cancer Institute, has confirmed…
-
Huadong Medicine’s HDM1002 Receives FDA Approval for Clinical Trials
•
Huadong Medicine Co., Ltd (SHE: 000963), a leading China-based pharmaceutical company, has announced that it has received clinical trial approval from the US Food and Drug Administration (FDA) for its investigational drug HDM1002. This small molecule is a complete agonist of the GLP-1 receptor with oral activity, known for its…
-
Rona Therapeutics and Keymed Biosciences Collaborate on siRNA Therapeutics for Glomerulonephritis
•
China-based Rona Therapeutics Inc. and Keymed Biosciences (HKG: 2162) have unveiled a strategic collaboration aimed at the joint discovery and development of first-in-class siRNA therapeutics targeting glomerulonephritis, a group of severe kidney diseases. Rona will apply its proprietary RAZOR RNAi platform to identify siRNA lead compounds directed at a novel…
-
Omron Healthcare and JD Healthcare Form Partnership to Innovate Chronic Disease Management
•
At the China International Medical Equipment Fair (CMEF), Omron Healthcare, a leading provider of healthcare equipment, has announced a new partnership with JD Healthcare, a subsidiary of China’s e-commerce giant JD.com (NASDAQ: JD). This strategic alliance aims to establish a comprehensive chronic disease management system that integrates both online and…
-
LaNova Medicines and AstraZeneca Ink Global Licensing Deal for GPRC5D-Targeting ADC LM-305
•
Shanghai-based LaNova Medicines Ltd, a developer of cancer therapies, has announced a significant global licensing deal with UK pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN). The agreement concerns LM-305, a pre-clinical antibody drug conjugate (ADC) that targets GPRC5D. AstraZeneca will receive exclusive global rights to research, develop, and commercialize LM-305, in…
-
ExoRNA Bio Secures Tens of Millions in Financing to Advance Huntington’s Disease Pipeline
•
ExoRNA Bio, a Shenzhen-based central nervous system (CNS) drug developer, has reportedly raised tens of millions of renminbi in an angel+ financing round. The round was led by Yuexiu Industrial Fund, with participation from Jingxin Pharma, Dingxin Capital, Nanjing University Biopharmaceutical Industry Alumni Association, and existing investor CDH Investments. The…
-
Luye Pharma’s Boan Biotechnology Partners with GenScript on GenCircle dsDNA Development
•
Shandong Boan Biotechnology Co., Ltd, a controlling subsidiary of China-based Luye Pharma Group (HKG: 2186), has entered into a strategic partnership with GenScript Biotech Corporation (HKG: 1548), a leading Contract Research Organization (CRO). The collaboration aims to develop and manufacture the small circular double-stranded DNA vector GenCircle dsDNA, which is…
-
Betta Pharmaceuticals and EyePoint Pharmaceuticals Submit EYP-1901 for NMPA Review
•
China’s Betta Pharmaceuticals (SHE: 300558) has announced that the clinical trial filing for its EYP-1901 intravitreal implant, co-filed with EyePoint Pharmaceuticals, Inc (NASDAQ: EYPT), has been accepted for review by the National Medical Products Administration (NMPA). The drug is intended to be assessed as a potential treatment for pathological myopia…
-
Basecare Medical to Acquire BMX Holdco for $40 Million, Expanding IVF Portfolio
•
China-based in vitro fertilization (IVF) specialist, Suzhou Basecare Medical Co., Ltd (HKG: 2170), has announced its intention to acquire 100% stakes in Singapore-headquartered BMX Holdco Pte. Ltd for a sum of $40 million. The acquisition will see BMX becoming a wholly-owned subsidiary of Basecare upon deal closure. BMX Holdco Pte.…
